RadioMedix and Thor Medical enter supply agreement for thorium-228

(Oslo Bors:TRMED), OSLO, Norway and HOUSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) — Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, and RadioMedix, Inc., a U.S. based clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and cancer therapy, have entered into a five-year frame agreement for the […]

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

(NASDAQ:PPBT),(TASE:PPBT.TA), New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance,

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

(NYSE MKT:CATX), SEATTLE, Dec. 04, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted for presentation at the American Society of Clinical Oncology Gastrointestinal Cancers

Secure Legion Launches Public Beta of the First Metadata-Free Messaging Platform

Cheyenne, WY, USA, Dec. 04, 2025 (GLOBE NEWSWIRE) — Secure Legion has announced the public beta release of the world's first messaging application designed to expose zero metadata. Built entirely without servers, directories, or intermediaries, the platform delivers fully peer-to-peer communication through Tor hidden services ensuring that no third party can observe who is communicating,

Redpoint Global Named a Leader and Ace Performer in the Spark Matrix (TM): Data Quality & Observability Tools, 2025 by QKS Group

Wellesley MA, Dec. 04, 2025 (GLOBE NEWSWIRE) — QKS Group has named Redpoint Global, The Data Readiness Company, as a Leader and Ace Performer in their SPARK Matrix(TM): Data Quality and Observability Tools, 2025. The QKS Group SPARK Matrix(TM) offers an in-depth analysis of global market dynamics, major trends, vendor landscapes, and competitive positioning. By

Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors

(TSX-V:VXL), Not for distribution by US newswire or in United States TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) — VAXIL BIO LTD. (“Vaxil” or the “Company“) (TSX VENTURE: VXL), is pleased to announce that the Company completed its previously announced non-brokered private placement (see press release dated November 24, 2025) for gross proceeds of $140,000 (the

Plug Power Signs Letter of Intent with Hy2gen for 5MW PEM Electrolyzer Supporting France’s Hydrogen Roadmap at Sunrhyse Green Hydrogen Project

(NASDAQ:PLUG), Agreement advances renewable, RFNBO-certified hydrogen production in southern France. Partnership supports logistics and mobility decarbonization across the Provence-Alpes-Cote d'Azur region. Project expands Plug's European footprint through collaboration with Hy2gen on green hydrogen solutions. SLINGERLANDS, N.Y., Dec. 04, 2025 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for

HEROES, HEART & HOPE GALA RAISES OVER $2.4 MILLION TO EXPAND ACCESS TO ADAPTIVE SPORTS, GRANTS AND INCLUSIVE PROGRAMS IN THE NORTHEAST

New York, NY, Dec. 04, 2025 (GLOBE NEWSWIRE) — The Challenged Athletes Foundation's (CAF) 19th annual Heroes, Heart & Hope Gala returned to Casa Cipriani South in New York City on Monday, November 17, raising over $2.4 million to support life-changing grants for adaptive sports equipment, coaching, clinics, travel, and inclusive school-based programs that open

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

(NASDAQ:MPLT), Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026 Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer's disease psychosis expected in the second half of 2027 Raised $296.5 million in gross proceeds from initial public offering and concurrent private placement completed in

Scroll to Top